Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of PT523 [talotrexin] in patients with solid tumors

Trial Profile

A phase I study of PT523 [talotrexin] in patients with solid tumors

Phase of Trial: Phase I

Latest Information Update: 28 Nov 2013

At a glance

  • Drugs Talotrexin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 24 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top